Ocular Therapeutix posts mixed Q4 results

Ocular Therapeutix logoShares in Ocular Therapeutix (NSDQ:OCUL) fell in premarket activity today after the company posted mixed fourth-quarter results.

The Bedford, Mass.-based company posted a net loss of -$17.4 million, or -42¢ per share, on sales of $504,000 for the three months ended Dec. 31, for sales growth of 3.5% compared with the same period last year.

Get the full story at our sister site, Drug Delivery Business News.

The post Ocular Therapeutix posts mixed Q4 results appeared first on MassDevice.

InfuSystem reports Q4, FY18 financial results

InfuSystem - updated logoShares in InfuSystem (NYSE:INFU) ticked up slightly today after the company reported its fourth-quarter and full-year financial results.

The Michigan-based company posted a net loss of -$275k, or -1¢ per share, on sales of $17.6 million for the three months ended Dec. 31. Sales were down 7% compared to the same period last year.

Get the full story at our sister site, Drug Delivery Business News.

The post InfuSystem reports Q4, FY18 financial results appeared first on MassDevice.

Tandem addresses anomaly in pivotal trial for closed-loop tech

Tandem Diabetes Care - updatedTandem Diabetes Care (NSDQ:TNDM) said today that it plans to use its remote software update tool to address an anomaly found in an ongoing pivotal trial of its Control-IQ technology.

The anomaly, according to Tandem, relates to how the company’s t:slim X2 insulin pump with Control-IQ technology handles continuous glucose monitoring data under undisclosed conditions. The company reported that the anomaly could impact the system’s prediction of future blood glucose values and automated insulin delivery.

Get the full story at our sister site, Drug Delivery Business News.

The post Tandem addresses anomaly in pivotal trial for closed-loop tech appeared first on MassDevice.

FDA approves J&J’s nasal spray for treatment-resistant depression

Johnson & JohnsonThe FDA has approved Johnson & Johnson‘s (NYSE:JNJ) esketamine nasal spray for people living with treatment-resistant depression.

The company’s product, Spravato, is an intranasal formulation of ketamine – a horse tranquilizer that is also known as Special K. The drug won support for approval from an FDA advisory committee earlier this year.

Get the full story at our sister site, Drug Delivery Business News.

The post FDA approves J&J’s nasal spray for treatment-resistant depression appeared first on MassDevice.

Valeritas posts mixed Q4 results

Valeritas logo - updatedValeritas (NSDQ:VLRX) posted its fourth-quarter and full-year financial results today, missing earnings estimates but topping revenue expectations on Wall Street.

The Bridgewater, N.J.-based company posted a net loss of -$11.9 million on sales of $6.89 million for the three months ended Dec. 31, for sales growth of 19% compared with the same period last year.

Get the full story at our sister site, Drug Delivery Business News.

The post Valeritas posts mixed Q4 results appeared first on MassDevice.

Teva launches generic for Pfizer’s Flector pain patch

Teva updated logoTeva (NYSE:TEVA) said last week that it launched a generic version of Pfizer‘s (NYSE:PFE) Flector diclofenac epolamine patch.

Using a nonsteroidal anti-inflammatory drug, the topical patch is designed to treat acute pain due to minor strains, sprains and contusions.

Get the full story at our sister site, Drug Delivery Business News.

The post Teva launches generic for Pfizer’s Flector pain patch appeared first on MassDevice.

Medtronic updates on corrected safety analysis for paclitaxel-coated balloon

Medtronic logo updatedMedtronic (NYSE:MDT) said last week that a revised safety analysis of its In.Pact drug-coated balloon has been accepted by the Journal of the American College of Cardiology.

Last month, the medtech titan reported that a programming error inadvertently caused mortality data to be omitted from a statistical analysis involving the company’s paclitaxel-coated balloon.

Get the full story at our sister site, Drug Delivery Business News.

The post Medtronic updates on corrected safety analysis for paclitaxel-coated balloon appeared first on MassDevice.

Rani debuts human trial data for robotic pill tech

Rani TherapeuticsRani Therapeutics this week touted the results of a first-in-human feasibility trial for its swallowable robotic pill, the RaniPill.

Rani has developed a capsule that delivers an intestinal injection of medicine without exposing the drugs to digestive enzymes.

Get the full story at our sister site, Drug Delivery Business News.

The post Rani debuts human trial data for robotic pill tech appeared first on MassDevice.

Oyster Point raises $93m for intranasal dry eye disease therapies

Oyster Point Pharma logoOyster Point Pharma said yesterday that it raised $93 million in a Series B round to support the clinical development of its intranasal dry eye disease therapies.

The Princeton, N.J.-based company’s lead product candidates for dry eye disease are designed to stimulate the trigeminal parasympathetic pathway to trigger natural tear film production. The drugs, OC-01 and OC-02, are delivered using an ocular surface-sparing nasal spray.

Get the full story at our sister site, Drug Delivery Business News.

The post Oyster Point raises $93m for intranasal dry eye disease therapies appeared first on MassDevice.

Mylan shares down on mixed Q4 results

Mylan logo - updatedShares in Mylan (NSDQ:MYL) fell yesterday after the company missed earnings expectations but beat sales estimates on Wall Street with its fourth-quarter financial results.

The Pittsburgh, PA-based company posted profits of $51.2 million, or 10¢ per share, on sales of $3.04 billion for the three months ended Dec. 31, for bottom-line loss of -79% on sales loss of -5% compared with the same period last year.

Get the full story at our sister site, Drug Delivery Business News.

The post Mylan shares down on mixed Q4 results appeared first on MassDevice.